Biointron Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2012

Location

Shanghai China

Primary Industry

Biotechnology

About

Based in Jiangsu, China and established in 2012, Biointron operates as a contract research organization (CRO) vendor that engages in recombinant antibody drug R&D and related outsourcing services. The company has R&D and production center located in Jiangsu and business center located in the USA and Netherlands. It has more than 400 employees and over 14,600 square meter production area. The company provides recombinant protein and antibody reagents for biotech and biopharma companies. The company develops high throughput recombinant antibody expression platform, phage library antibody development platform and single cell antibody development platform. It adopts microfluidic sorting and identification technologies. The business of the company includes antibody discovery, antibody production, stable cell line and protein expression. Antibody discovery include VHH library generation, single B cell screening, hybridoma sequencing, antibody humanization and affinity maturation.

Current Investors

Zehou Capital, Rimonci Capital, CoStone Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Outsourcing, Biotechnology

Website

www.biointron.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.